BIOMAT Database Logo BIOMAT Database Logo

Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. 1998

E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
First Department of Surgery, School of Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.

Glucagon is commonly used during gastrointestinal examinations for the temporary inhibition of gastroduodenal movements. Three preparations of glucagon are now clinically available: those prepared by extraction from the pancreas (GL-P), by chemical synthesis (GL-S), and by genetic recombination (GL-G). The aim of this study was examine the mechanism of the inhibitory effect of glucagon on gastrointestinal motility and the cause of its side effects by comparing three glucagon preparations. In four conscious dogs, gastrointestinal contractions were monitored by means of chronically implanted force transducers. Each glucagon preparation (GL-P [15 microg/kg], GL-S [5, 15, 45 microg/kg], GL-G [15 microg/kg]), scopolamine butylbromide (0.4 mg/ kg), or saline was administered intravenously 20 min after the termination of spontaneous phase III contractions, and blood samples were taken at 5- to 10-min intervals. Barium was administered into the stomach 10 min after the infusion of each drug. The arrival of a barium meal in the stomach immediately stimulated gastrointestinal contractions, and the barium meal was expelled into the duodenum and jejunum from the stomach. Intravenous injection of 15 microg GL-S first stimulated duodenal contractions that propagated to the jejunum, followed by strong inhibition of the barium-induced gastrointestinal contractions. This inhibitory effect of glucagon and the activity of the glucagon-induced duodenal contractions were dose-related. The inhibitory effects of GL-G and GL-S were stronger than that of GL-P. Blood glucose and plasma insulin concentrations were raised after intravenous injection of each glucagon preparation, but there was no difference among the three preparations and no dose relationship. The inhibitory effects of glucagon depend on the material purity and dose, and the inhibitory mechanism was independent of any effect on carbohydrate metabolism. Glucagon administration caused phase III-like contractions in the duodenum and jejunum, which may be responsible for the side effects of glucagon.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004064 Digestive System A group of organs stretching from the MOUTH to the ANUS, serving to breakdown foods, assimilate nutrients, and eliminate waste. In humans, the digestive system includes the GASTROINTESTINAL TRACT and the accessory glands (LIVER; BILIARY TRACT; PANCREAS). Ailmentary System,Alimentary System
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug

Related Publications

E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Effect of glucagon on gastrointestinal motility.
January 1966, The American journal of gastroenterology,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
[Inhibitory effect of clonidine on gastrointestinal motility].
January 1988, Yao xue xue bao = Acta pharmaceutica Sinica,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.
November 2001, British journal of pharmacology,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Inhibitory effects of calcitonin gene-related peptide on gastrointestinal motility.
June 1992, Annals of the New York Academy of Sciences,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Progesterone inhibitory role on gastrointestinal motility.
April 2022, Physiological research,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
[Comparative study on the inhibitory effect of glucagon and secretin on the gastroduodenal motility in man].
December 1984, Nihon Heikatsukin Gakkai zasshi,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Supraspinal inhibitory effects of chimeric peptide MCRT on gastrointestinal motility in mice.
September 2017, The Journal of pharmacy and pharmacology,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
[Effect of corticosterone, glucagon and growth hormone on gastrointestinal propulsive motility in rats (author's transl)].
April 1976, Bratislavske lekarske listy,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
[Comparative studies on pancreas glucagon and secretion effect on motility of proximal and distal human gastrointestinal tract].
January 1973, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
E Mochiki, and H Suzuki, and S Takenoshita, and Y Nagamachi, and H Kuwano, and A Mizumoto, and Z Itoh
Inhibitory effect of glucagon on erythropoiesis.
June 1980, Blood,
Copied contents to your clipboard!